Quince Therapeutics, Inc. (Nasdaq: QNCX), a biopharmaceutical company advancing innovative precision therapeutics targeting debilitating and rare diseases, today detailed highlights from the company’s participation at The American Society for Bone and Mineral Research Annual Meeting (ASBMR 2022), which took place September 9 to September 12, 2022, in Austin, Texas. At ASBMR 2022, Quince presented two posters showcasing the broad applicability of the company’s highly differentiated bone-targeting platform and potential to accelerate healing directly at the site of bone injury and disease in spinal fusion and bone cancer indications.

Stewart Low, Quince’s head of discovery, said, “Supported by more than 10 years of extensive preclinical studies, we believe Quince’s proprietary bone-targeting platform can be harnessed to enable the precise delivery of drug concentrated directly to the site of bone injury and disease to accelerate healing. We are excited to continue to bring our preclinical research forward to demonstrate the potential of our proprietary targeting platform with additional indications in spinal fusion and bone cancer as we seek to improve outcomes in underserved patient populations.”

ASBMR 2022 Poster Highlights

The following are highlights from the company’s poster presentations of preclinical data exploring spinal fusion and bone cancer indications at ASBMR 2022:

Poster: Improved Spinal Fusion Through Targeted Delivery of Abaloparatide

• With more than 400,000 spinal fusions performed in the U.S. every year, Quince believes there is an opportunity to utilize its bone-targeting platform to improve patient outcomes in spinal fusion with its NOV004 targeted therapeutic.
• Quince developed a bone-targeting compound based on acidic oligopeptides which is designed to stimulate bone growth at spinal fusion sites.
• In preclinical studies, NOV004 concentrated at spinal fusion sites to demonstrate accelerated repair in treated animals which resulted in significantly improved blinded radiographic fusion scores compared to animals treated with the current standard of care, bone morphogenic protein-2 (BMP-2).
• In addition, NOV004’s subcutaneous administration would allow for repeat dosing post operatively compared to current spinal fusion strategies that generally require surgery to apply the drug and only allow for one application.

Poster: Evaluating the Efficacy of an Acidic Oligopeptide-radioisotope Chelator Conjugate to Target and Deliver Radioactive Agents to Bone Cancers

• With five-year survival rates of less than 20% to 30% in patients with breast and prostate cancer related bone metastases, Quince believes there is an opportunity to utilize its bone-targeting platform to develop targeted radiotherapeutics to improve patient outcomes in breast and bone cancer related bone tumor growth.
• Quince developed a radioactive acidic oligopeptide conjugate to target and deliver imaging and therapeutic agents with high tumor-bearing bone specificity.
• In preclinical studies, the company confirmed that its targeting moiety can localize to metastatic tumor sites in both osteolytic and osteoblastic lesions and can selectively deliver both fluorescent dye and radioisotope-chelated agents without obvious offsite localization.
• In addition to demonstrating rapid renal excretion, the radioactive conjugates were retained in the diseased bone even at two weeks post injection.

To view the posters presented at ASBMR 2022, please visit the Science section of Quince’s corporate website.

About Quince Therapeutics

Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.

Forward-looking Statements

Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “anticipate,” “expect,” “will,” “can,” “may,” “should,” “estimate,” “project,” “potential,” “encouraged,” “positioned,” or other similar words. Examples of forward-looking statements include, among others, the clinical development and strategic development path for NOV004; the timing and success of the company’s clinical trials and related data, including plans and the ability to initiate, conduct and/or complete the Phase 1 clinical studies for NOV004; the potential therapeutic benefits, safety, and efficacy of the company’s bone-targeting platform, product candidate and discovery pipeline. Forward-looking statements are based on Quince Therapeutic’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in the company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 1, 2022, its Quarterly Report on Form 10-Q filed with the SEC on August 9, 2022, and other reports as filed with the SEC. Forward-looking statements contained in this news release are made as of this date, and Quince Therapeutics undertakes no duty to update such information except as required under applicable law.